New research reveals how ezogabine targets potassium channels in the brain, offering innovative treatment options for major depressive disorder symptoms.
Elizabeth Dowling
Advertisement
Ms Dowling is the senior director of Public Affairs and Media at Mount Sinai Health System.
Articles by Elizabeth Dowling
"Our findings provide a mechanistic explanation for the well-known variations in individual responses to drugs and suggest that subjective beliefs could be a direct target for the treatment of substance use disorders," said Xiaosi Gu, PhD, senior author of the study.
Researchers identified 298 genetic regions linked to bipolar disorder risk in the largest study of its kind.
Advertisement
Latest Updated Articles
Largest Genetic Study of Bipolar Disorder Identifies 298 Regions of the Genome That Increase Risk for the ConditionPublished: February 16th 2025 | Updated:
Mount Sinai Study Shows That Human Beliefs About Drugs Could Have Dose-Dependent Effects on the BrainPublished: March 1st 2025 | Updated:
Advertisement
Advertisement
Trending on Psychiatric Times
1
Increased Risk of Death in Patients With Dementia Found Related to Common Hospice Medications
2
Loneliness, Meet Solitude
3
How to Approach Conversations With Adult Patients Who Might Have ADHD: New Tools and Insights
4
FDA Approves Uzedy Once-Monthly Extended Release Injectable Suspension for Bipolar I Disorder
5
